Revance Therapeutics Future Growth
Future criteria checks 5/6
Revance Therapeutics is forecast to grow earnings and revenue by 70.6% and 21.9% per annum respectively while EPS is expected to grow by 72.6% per annum.
Key information
70.6%
Earnings growth rate
72.6%
EPS growth rate
Pharmaceuticals earnings growth | 21.5% |
Revenue growth rate | 21.9% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 10 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 430 | -22 | 55 | 26 | 9 |
12/31/2025 | 344 | -93 | -35 | -24 | 9 |
12/31/2024 | 266 | -156 | -108 | -53 | 8 |
9/30/2024 | 257 | -303 | -195 | -191 | N/A |
6/30/2024 | 251 | -304 | -209 | -201 | N/A |
3/31/2024 | 240 | -325 | -221 | -213 | N/A |
12/31/2023 | 234 | -324 | -223 | -217 | N/A |
9/30/2023 | 204 | -292 | -210 | -204 | N/A |
6/30/2023 | 179 | -337 | -214 | -211 | N/A |
3/31/2023 | 153 | -341 | -204 | -202 | N/A |
12/31/2022 | 133 | -356 | -197 | -194 | N/A |
9/30/2022 | 109 | -274 | -214 | -208 | N/A |
6/30/2022 | 99 | -263 | -210 | -203 | N/A |
3/31/2022 | 90 | -274 | -216 | -208 | N/A |
12/31/2021 | 78 | -281 | -232 | -222 | N/A |
9/30/2021 | 63 | -297 | -247 | -239 | N/A |
6/30/2021 | 47 | -303 | -250 | -242 | N/A |
3/31/2021 | 29 | -292 | -218 | -210 | N/A |
12/31/2020 | 15 | -282 | -183 | -179 | N/A |
9/30/2020 | 4 | -249 | -152 | -150 | N/A |
6/30/2020 | 0 | -209 | -129 | -126 | N/A |
3/31/2020 | 0 | -186 | -141 | -138 | N/A |
12/31/2019 | 0 | -159 | -109 | -106 | N/A |
9/30/2019 | 1 | -155 | -108 | -104 | N/A |
6/30/2019 | 3 | -146 | -103 | -97 | N/A |
3/31/2019 | 4 | -143 | -112 | -105 | N/A |
12/31/2018 | 4 | -143 | -111 | -104 | N/A |
9/30/2018 | 3 | -138 | -107 | -102 | N/A |
6/30/2018 | 1 | -136 | N/A | -98 | N/A |
3/31/2018 | 0 | -128 | N/A | -85 | N/A |
12/31/2017 | 0 | -121 | N/A | -95 | N/A |
9/30/2017 | 0 | -111 | N/A | -80 | N/A |
6/30/2017 | 0 | -99 | N/A | -73 | N/A |
3/31/2017 | 0 | -97 | N/A | -65 | N/A |
12/31/2016 | 0 | -89 | N/A | -60 | N/A |
9/30/2016 | 0 | -85 | N/A | -63 | N/A |
6/30/2016 | 0 | -86 | N/A | -62 | N/A |
3/31/2016 | 0 | -78 | N/A | -58 | N/A |
12/31/2015 | 0 | -73 | N/A | -56 | N/A |
9/30/2015 | 0 | -66 | N/A | -48 | N/A |
6/30/2015 | 0 | -60 | N/A | -47 | N/A |
3/31/2015 | 0 | -57 | N/A | -47 | N/A |
12/31/2014 | 0 | -63 | N/A | -55 | N/A |
9/30/2014 | 1 | -49 | N/A | -60 | N/A |
6/30/2014 | 1 | -48 | N/A | -54 | N/A |
3/31/2014 | 1 | -38 | N/A | -62 | N/A |
12/31/2013 | 1 | 0 | N/A | -48 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RTI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: RTI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RTI is expected to become profitable in the next 3 years.
Revenue vs Market: RTI's revenue (21.9% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: RTI's revenue (21.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RTI's Return on Equity is forecast to be high in 3 years time